title: Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province).
abstract: BACKGROUND
  CYP2D6 is polymorphically expressed enzyme that show marked interindividual and interethnic variation. Phenotyping of CYP2D6 provides valuable information about real-time activity of this important drug-metabolizing enzymes through the use of specific probe drugs. The aim of this study was to identify the CYP2D6 oxidation phenotype with dextromethorphan (DEX) as a probe drug in Mazandarani ethnic group among Iranian population.
  
  
  METHODS
  The study included 71 unrelated healthy volunteers. Dextromethorphan hydrobromide (30 mg) was given orally to healthy subjects and peripheral venous blood samples (10 ml) were taken at 3 hr post-dose. Dextromethorphan and the metabolite dextrorphan (DOR) were analyzed by the HPLC method. The log DEX/DOR metabolic ratio (MR) at 3 hr plasma sample was used as the index of CYP2D6 activity and a value of 0.3 was used as the antimode separating extensive metabolizers (EM) and poor metabolizers (PM) phenotypes.
  
  
  RESULTS
  A 560-fold interindividual variation in dextromethorphan MRs was observed in this study. Considering the antimode 0.3 in log scale, 7.04% (5/71) volunteers were identified as PMs. Conclusion : The result showed that the frequency of CYP2D6 PM phenotypes accounted for 7.04% of subjects in our samples. Despite these findings, we propose a further study in larger samples to provide a wider image and to get more valuable information upon pharmacogenetic basis for individual therapy and personalized medicine.
authors.affiliation: Psychiatry and Behavioral Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran .
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Shiran
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Sarzare
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Merat
authors.forename: Ebrahim
authors.initials: E
authors.lastname: Salehifar
authors.forename: Ali Akbar
authors.initials: AA
authors.lastname: Moghadamnia
authors.forename: Seyed Mohammad Bagher
authors.initials: SM
authors.lastname: Hashemi Soteh
keywords: CYP2D6; Dextromethorphan; Iran; Mazandaran; Phenotype; Polymorphism
references.citation: Genet Test Mol Biomarkers. 2009 Oct;13(5):665-70
references.pmid: 19715474
references.citation: Cell Biochem Funct. 2006 Sep-Oct;24(5):381-5
references.pmid: 16130179
references.citation: Pharmacogenomics J. 2005;5(1):6-13
references.pmid: 15492763
references.citation: Int J Neuropsychopharmacol. 1998 Dec;1(2):173-185
references.pmid: 11281961
references.citation: Clin Pharmacokinet. 1995 Sep;29(3):192-209
references.pmid: 8521680
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
references.pmid: 14618296
references.citation: Eur J Clin Pharmacol. 1993;45(3):271-3
references.pmid: 8276053
references.citation: Eur J Clin Pharmacol. 2002 Nov;58(8):533-5
references.pmid: 12536989
references.citation: Eur J Drug Metab Pharmacokinet. 1996 Oct-Dec;21(4):301-7
references.pmid: 9074894
references.citation: Eur J Drug Metab Pharmacokinet. 1996 Oct-Dec;21(4):309-14
references.pmid: 9074895
references.citation: J Biomed Sci. 2003 Sep-Oct;10(5):552-64
references.pmid: 12928596
references.citation: Int J Clin Pharmacol Res. 2003;23(1):31-5
references.pmid: 14621071
references.citation: Pharmacol Res. 1994 Apr;29(3):281-9
references.pmid: 8058599
references.citation: Psychopharmacol Bull. 1998;34(4):797-804
references.pmid: 10513455
references.citation: Pharmacogenetics. 1997 Jun;7(3):193-202
references.pmid: 9241659
references.citation: Drug Metab Rev. 2002 Feb-May;34(1-2):83-448
references.pmid: 11996015
references.citation: Clin Pharmacol Ther. 1988 Oct;44(4):431-5
references.pmid: 3168394
references.citation: Pharmacogenetics. 1995 Apr;5(2):64-71
references.pmid: 7663530
references.citation: Pharmacogenetics. 1996 Oct;6(5):441-7
references.pmid: 8946476
references.citation: Clin Pharmacol Ther. 2001 Dec;70(6):552-60
references.pmid: 11753272
references.citation: Eur J Clin Pharmacol. 2005 Nov;61(10):749-54
references.pmid: 16249913
references.citation: Eur J Clin Pharmacol. 2005 Feb;60(12):849-54
references.pmid: 15657780
references.citation: J Clin Pharm Ther. 2000 Oct;25(5):379-83
references.pmid: 11123490
references.citation: Ther Drug Monit. 1990 Jan;12(1):97-104
references.pmid: 2305428
references.citation: Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):1-5
references.pmid: 9625265
references.citation: Eur J Clin Pharmacol. 1999 May;55(3):177-84
references.pmid: 10379632
references.citation: Lancet. 2000 Nov 11;356(9242):1667-71
references.pmid: 11089838
references.citation: Clin Pharmacol Ther. 1992 Apr;51(4):388-97
references.pmid: 1345344
references.citation: Pharmacogenetics. 1999 Oct;9(5):601-5
references.pmid: 10591540
references.citation: Am J Hum Genet. 1997 Feb;60(2):284-95
references.pmid: 9012401
references.citation: Br J Clin Pharmacol. 2000 Jul;50(1):31-4
references.pmid: 10886115